ArticleCancers2022

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Hannah L Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.